Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, a biopharmaceutical company that discovers, develops and commercialises therapeutics in areas of unmet medical need, has filed a lawsuit in US District Court in New Jersey against Lupin for infringement against Gilead's patents for Ranexa (ranolazine extended-release tablets).
Subscribe to our email newsletter
Gilead Sciences’ lawsuit against Lupin is based on an abbreviated new drug application filed by Lupin, seeking approval to manufacture and market a generic version of Ranexa before the expiration of Gilead’s Ranexa patents.
Ranexa is an anti-anginal medication. It works by improving blood flow to help the heart work more efficiently.
Ranexa is used to treat chronic angina (chronic chest pain). It may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Gilead Sciences said that Ranexa is currently protected by 10 patents, which are listed in the approved drug products list of FDA and all 10 patents would need to be invalidated, expire or not be infringed before a generic version of Ranexa could be marketed.